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Introduction
The pharmacokinetics of metformin, a first-line drug therapy for type 2 diabetes (DM2), is modulated by several transmembrane transporters, notably organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs), encoded by SLC22 and SLC47 genes, respectively [1, 2] . OCT1 (SCL22A1) and OCT3 (SCL22A3) contribute to the extrusion of metformin from enterocytes into blood. Conversely, OCT1 and to a lesser extent OCT3 promote the uptake of metformin into hepatocytes, essential for the drug's inhibitory effect on gluconeogenesis. Both OCT1 and OCT3 transport metformin into skeletal muscle, which may be a major site of the drug's action. OCT2 (SCL22A2) expressed in the basolateral membrane of renal tubule cells, mediate cellular influx of metformin, whereas MATE1 (SLC47A1) and MATE2 (SLC47A2), present in the apical membrane extrude the drug out of the tubule lining cells into urine. OCT1 has also been detected in the apical membranes of proximal and distal tubules, and may be involved in metformin resorption [3] .
The impact of OCT and MATE transporters on metformin pharmacokinetics is subject to modulation by coadministered drugs, that inhibit or induce the transporters [4, 5] , by genetic polymorphisms affecting expression and/or function of the transport proteins and their transcription factors, and by gene-gene interactions [6] [7] [8] [9] [10] . Metformin pharmacogenetics has been extensively investigated in European and Asian populations, with controversial results regarding the drug's pharmacokinetics and clinical effects. The present study explores the impact of pharmacogenetic variants on metformin pharmacokinetics in a Brazilian cohort of healthy adults. The present day Brazilian population of over 200 million, is highly heterogeneous and admixed, a fact that has far reaching pharmacogenetics implications [11] [12] [13] . The extent of admixture is well documented in a wealth of population genetic studies in Brazilians, and it is evident that most individuals have significant degrees of European and/or African ancestry, while a sizeable number display also Amerindian ancestry [14, 15] . Based on previous reports of association with metformin pharmacokinetic parameters, 11 single-nucleotide polymorphisms (SNPs) in SCL22A1, SCL22A2, SCL47A1, SCL47A2 and in the transcription factor SP1 (specificity protein 1) locus were selected for this study. The participants were also typed with a panel of ancestry informative markers to estimate the influence of individual proportions of Amerindian (Native), African and European ancestry on metformin pharmacokinetics.
Methods

Study cohort
We used demographic and pharmacokinetic data available for 256 healthy, adult Brazilians previously enrolled in nine bioequivalence trials, performed according to the guidelines of the Brazilian Health Surveillance Agency [16] and approved by the respective institutional review boards. Each volunteer (24-34 per trial) provided written, informed consent and was asked to self-identify according to the race/ Colour classification scheme adopted by the Brazilian census, which relies on self-perception of skin colour [17] . The term Colour and the Colour categories are capitalized to call attention to their meaning in the context of the Brazilian Census, Colour (in Portuguese, cor) denoting the Brazilian equivalent of the English term race. Details of the study protocol were reported previously [18] . Briefly, the bioequivalence trials adopted an open-label, randomized, two-sequence, twoperiod crossover design, in which administration of the reference (Glifage; Merck & Co., Rio de Janeiro, Brazil) and a test metformin formulation were separated by a 7-day washout interval. The oral metformin doses were 500 mg (four trials) and 1000 mg (five trials). Metformin was administered after a 12-h fast in four trials and 30 min after a standard low-fat breakfast in five trials. Consecutive blood samples (n = 14-18) were collected immediately before and in the 48 h following metformin administration. The concentration of metformin in plasma was determined by liquid chromatography-tandem mass spectrometry, and linear trapezoidal interpolation was used to determine the area under the plasma concentration vs. time curve between 0 and 48 h (AUC 0-48h ). All statistical analyses were performed on log-transformed AUC 0-48h, adjusted for the individual doses, expressed as ng h ml À1 mg (dose) À1 .
Extreme discordant phenotype
To increase the statistical power of the study to detect associations of genetic and nongenetic variables with metformin AUC 0-48h we applied the extreme discordant phenotype (EDP) methodology [19] . The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual metformin AUC 0-48h correspond to the lower and upper ends of the distribution histogram. Data sets for the reference formulation from the 256 individuals enrolled in the bioequivalence trials were used to construct the distribution histogram of the AUC 0-48h . The cut-off point for selection of individuals to be recruited for the study was set at the 20 th percentile of the overall study cohort (n = 256), which corresponds to 51 individuals. As a preventive measure in the case of missing genotype data, two additional subjects from each end of the distribution histogram were recruited. Only these 106 individuals (2 × 53) were genotyped for pharmacogenetic polymorphisms and for ancestry informative markers, as described below.
Genetic component of metformin pharmacokinetics
The repeated drug administration (RDA) method for estimating the genetic component (r GC ) of pharmacokinetic variation [20] was applied to the dose-adjusted, log-transformed AUC 0-48 values for the reference and the test formulations administered to the 106 subjects selected for this study. The between-(SD b 2 ) and within-person (SD w 2 ) variances were calculated and the expression r GC = (SD b 2 -SD w 2 )/ SD b 2 was used to estimate the genetic component of interindividual variability in AUC 0-48. Accordingly, r GC values approaching 1.0, point to overwhelming genetic control, whereas r GC values close to zero suggest that environmental factors dominate. Our rationale for adopting the RDA approach is that application of bioequivalent drug formulations mimics repeated administration of a given formulation, as originally proposed for the r GC analyses [20] .
Genotyping
Genomic DNA was isolated from peripheral blood by standard procedures. Taqman assays and a Fast 7500 Real-Time System (Applied Biosystems, Foster City, CA, USA) were used for allele discrimination at 11 polymorphic loci in SLC22A1, SLC22A2, SLC47A1, SCL47A2 and the SP1 locus (Table 1) . SNPs were selected on the basis of previous reports of association with metformin pharmacokinetic parameters. Allele and genotype frequency were derived by gene counting. Deviations from Hardy-Weinberg equilibrium were assessed by the goodness-of-fit χ 2 test.
Linkage disequilibrium and haplotype analyses
Pairwise linkage disequilibrium (LD) analyses of polymorphisms in SLC22A1, SLC47A1 and SP1 genes were conducted online using the CUBEX software [21] . The level of LD between loci was assessed using the coefficients D´and r 2 .
SLC22A1 haplotypes, comprising rs1867351, rs622342, rs12208357, rs72552763 and rs34059508 were statistically inferred using the software Phase v2.1.1 [22] . Haplotypes are labelled by numbers preceded by Br (e.g. HapBr1, the wildtype haplotype), a reference to this Brazilian cohort. Haplotypes containing one or more variant alleles are designated variant haplotypes. Diplotypes were classified according to the number of wildtype haplotypes: homozygous wildtype (n = 2), heterozygous (n = 1) and homozygous variant (n = 0).
Estimation of individual admixture
The 106 individuals selected by the EDP approach were genotyped with a panel of biallelic short insertion-deletion (indel) polymorphisms, validated as ancestry informative Table 1 Single nucleotide polymorphisms genotyped in the study
markers for the Brazilian population [23] . The individual proportions of biogeographical ancestry (Amerindian, European and African) were estimated using the program Structure v.2.3.4 [24] .
Multivariate regression model
To select candidate variables for the modelling of metformin AUC 0-48h , we initially examined the independent effects of demographic variables, food effect (i.e. metformin administration to fast or fed individuals), the 11 genotyped SNPs and the inferred SLC22A1 diplotypes. Genetic variables were analysed according to codominant and dominant models.
In the latter, carriers of one or two copies of the variant alleles at the SLC22, SCL47 and SP1 SNPs and carriers of one or two copies of variant SLC22A1 halotypes were contrasted with the respective homozygotes for the variant wild-type SNP alleles and the SLC22A1 wild-type halplotype HapBr1. Discrete covariates entered the analysis transformed as dummy variables and their effects are described by electing a baseline category and comparing the transformed response predicted at this category with the remaining category or categories of interest. Variables that associated (P < 0.15) with the log-transformed, dose-adjusted metformin AUC 0-48h in the univariate analyses were considered further in multivariate regression models. Variables that associated (P < 0.05) with AUC 0-48h in successive multivariate analyses were included in the final model. The relative contribution of each variable to the model was estimated by the partial r 2 statistics, which measure the degree of association between two random variables, with the effect of a set of controlling random variables removed. We assessed the goodness of fit of our models based on the R 2 and R 2 -adjusted statistics. The former is a measure of how well the regression line approximates the observed data points. It can also be interpreted as the proportion of the total variance in the observed data that is explained by the model. Since R 2 always increases with the number of variables in the model, this measure can be accounted for by adjusting for the number of covariates in the model, yielding the statistics known as the adjusted R 2 .
Statistical analyses
Demographic variables are presented as median ± interquartile range (1-3). Allele, genotype and haplotype frequencies are shown with the respective 95% confidence intervals [95% confidence interval (CI)]. The log-transformed, dose adjusted AUC 0-48h is presented as mean ± standard deviation (SD). The software G*Power 3.1.9.2 [25] was used to calculate statistical power to detect differences in AUC 0-48h among genotypes and SLC22A1 haplotypes.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY [26] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [27] .
Results Table 2 presents demographic information for the 106 healthy adult individuals (52 women) included in the study. Four race/Colour categories of the Brazilian census were represented in the study cohort and distributed in excellent agreement with their prevalence in the overall Brazilian population [15] . The individual proportions of Amerindian, European and African biogeographical ancestry (Table 2 , Figure S1 ) varied widely among the participants, as anticipated from the structure of the heterogenous, admixed Brazilian population [13, 15] .
Metformin pharmacokinetics 
Genetic component of variability of systemic exposure to metformin
The dose-adjusted, log transformed AUC 0-48 data for the reference and the test formulations were used for the calculation of the r GC AUC 0-48h value , according to the RDA method [20] . A. B. Santoro et al.
For the 106 subjects selected based on the EDP approach, an r GC value of 0.93 (0.90-0.95, 95% CI) was obtained, which is suggestive of a strong genetic component in the variation in systemic exposure to metformin following single oral doses of 500-1000 mg. Table 3 shows the frequency distribution of alleles and genotypes at polymorphic loci in SLC22A1, SLC22A2, SLC47A1, SCL47A2 and in the SP1 region. Deviation from Hardy-Weinberg expectations was not observed at any locus. Table 3 Allele and genotype frequency in the study cohort The two SNPs in the SP1 locus, rs584888 and rs 784 892, were in strong LD, with pairwise D´= 1.0 and r 2 = 0.93.
Pharmacogenetic polymorphisms
Haplotype analysis of the five SCL22A1 SNPs identified nine haplotypes with frequencies greater than 1%, which together accounted for 99.5% of the overall genetic diversity ( 
Regression modelling of metformin AUC 0-48h
The initial univariate analyses assessed the independent effect of demographic variables (Table 2) , food vs. fasting prior to metformin administration, and pharmacogenetic variants (SNPs and SCL22A1 diplotypes). Using a cut-off value of P < 0.15 (Methods), the univariate analyses disclosed age, BSA, self-reported brown or black colour, individual proportions of African and European ancestry, feeding status, rs12208357 (dominant model) and rs1867351 (codominant model) as being associated with metformin AUC 0-48h (Table 5 ). None of the other nine SNPs nor the SLC22A1 diplytopes under dominant or codominant model, associated (P < 0.15) with the metformin AUC 0-48h . The covariates significantly associated with AUC 0-48h in the univariate analyses were then entered into multivariate regression modelling, which retained age, BSA, individual proportions of African ancestry, food effect and rs12208357 in the final model ( Table 5 ). The partial r 2 statistics showed that age (partial r 2 = 0.091) and food (0.083) had the largest influence on metformin AUC 0-48h , followed by BSA (0.050), rs12208357 (0.031) and African ancestry (0.029). Metformin AUC 0-48h increased with age, food and carriage of rs12208357, but was inversely associated with BSA and individual proportion of African ancestry. Based on the adjusted R 2 value, the final regression model explained 29.7% of the overall variability in metformin AUC 0-48h. Finally, prompted by the findings of Christensen et al. [8] we examined the interaction between the OCT2 (rs316019) and MATE1 (rs2252281) polymorphisms with respect to the systemic exposure to metformin. Of the 37 individuals homozygous for the rs2252281 reference allele (Table 3) , 28 were also homozygous for the rs316019 reference allele, nine were heterozygous and none was homozygous for the variant allele. The Table 4 SLC22A1 haplotypes in the study cohort which is consistent with the data on metformin clearance reported by of Christensen et al. [8] . However, the difference in AUC 0-48h between the rs316019 genotypes was not statistically significant (P = 0.21) in our study cohort.
Discussion
Pharmacokinetic data from bioequivalence trials in healthy adult Brazilians were used to identify pharmacogenetic markers associated with interindividual variability in the systemic exposure to metformin, assessed by the parameter AUC 0-48h . To increase statistical power to detect pharmacogenetic associations, we applied the EDP method [19] to 256 bioequivalence data sets available and selected 106 individuals from the opposite ends of the distribution histogram of the AUC 0-48h. We then applied the RDA method [20] to these 106 data sets, and obtained an r GC value of 0.93 (0.90-0.95), which suggests that the observed variability in the logtransformed dose-adjusted AUC 0-48h is largely under genetic control [20] . However, the multivariate regression modelling of the contribution of genetic and nongenetic covariates to the log-transformed metformin AUC 0-48h disclosed a minor contribution of the genetic variants investigated. Thus, of the 11 SNPs examined, only rs12208357 was retained in the final multivariate regression model, accounting for 3.1% of the total variability in systemic exposure to metformin. Of notice, diplotypes comprising rs12208357 and four other SNPs in SLC22A1 showed no association with metformin AUC 0-48h . The apparent quantitative discrepancy between the r GC and the multivariate regression analysis, may involve several factors. First, the r GC analysis was based on data from bioequivalence studies, in which the impact of environmental variables is considerably attenuated, due to the implicit strict control of timing of drug administration, food status, coadministered drugs or xenobiotics, smoking, alcohol intake etc. Consequently, it may be argued that the r GC obtained from bioequivalence trials overestimates the genetic component of pharmacokinetic variability. Nevertheless, a similarly high r GC value (0.94) was reported for the renal clearance of metformin measured in multiple occasions in individuals receiving the reference drug formulation [28] . This finding, taken as evidence for strong genetic control of metformin pharmacokinetic variability [28] , provides support for a similar interpretation of our results derived from bioequivalence trials. Second, we genotyped a selected number of SNPs in a set of metformin transporter genes, which did not include PMAT (SLC29A4), OCTN1 (SLC22A4) and the thiamine transporter, THTR-2 (SLC19A3), that may be determinants of metformin pharmacokinetics. Genome-wide association studies on metformin pharmacokinetics, might reveal additional variants that would account for the large difference in the pharmacogenomic impact inferred using the r GC method vs. multivariate regression modelling. In the related context of metformin pharmacodynamics, genome-wide association studies revealed two SNPs, one at a locus containing the ataxia telangiectasia mutated (ATM) gene and another in SLC2A2, encoding the facilitated glucose transporter GLUT2, that associated significantly with metformin-induced clinical response. Of note, metformin was not a substrate or an inhibitor of GLUT2 in Xenopus laevis oocytes [29, 30] . In addition, a recently published meta-analysis failed to detect significant effects of nine SNPs in metformin transporters (seven of which were also investigated in the present study) on the glycaemic response to metformin [10] .
The statistical power of this study to detect significant associations of individual SNPs and SLC22A1 diplotypes with metformin AUC 0-48h, is a third factor to be considered. Based on genotype frequencies and a dominant genetic model, the study was powered (β = 0.2, α = 0.05) to detect a genotype effect of reduction or increase of metformin AUC 0-48h ≥ 15% for rs12208357 and ≥10% for all other candidate SNPs, except the rare (MAF <0.01) rs34059508. Regarding the SLC22A1 diplotypes, there was statistical power to detect increase or decrease of metformin AUC 0-48h ≥10% under a dominant model and ≥15% under a recessive model. However, our two-step regression modelling adopted a nominal significance level of α = 0.15 in the initial, univariate analyses for selection of covariates to be entered into the multivariable regression analyses. Accordingly, a genotype or diplotype effect of reduction or increase of metformin AUC 0-48h >5% in the univariate analysis allowed inclusion of the respective covariate in the multivariate regression modelling. This was the case, of both rs12208357 and rs1867351, with P values of 0.08 and 0.15, respectively, in the univariate analyses ( Table 5) . The final regression model retained only rs12208357, which accounted for 3.1% of the variability of metformin AUC 0-48h in the study cohort.
The rs12208357 in SLC22A1 is a nonsynonymous transition (181C > T, R61C), first shown by Shu and colleagues [31, 32] to abolish OCT1 activity, leading to reduced metformin uptake into hepatocytes, attenuated effect of the drug on glucose tolerance tests and higher AUC. The latter finding was reproduced in the present study, despite differences in ethnicity, metformin dose and experimental protocol. The increased systemic exposure to metformin in carriers of rs12208357 conflicts with the increased renal clearance of metformin reported by Tvezkof et al. [33] . The latter observation, however, was not reproduced by Christensen and colleagues [34, 35] . The latter authors examined the influence of SLC22A1 (OCT1) diplotypes comprising rs12208357 and three other reduced-function alleles on the metformin plasma concentration at steady state, and found the trough value to decrease with increasing number of reduced-function haplotypes in DM2 patients [34] but not in healthy volunteers [35] . A statistical type 2 error inflicted by the small sample size of the healthy cohort (n = 12) was considered a possible explanation for these discordant observations [35] . However, in our considerably larger (n = 106) cohort of healthy subjects, diplotypes comprising the five genotyped SNPs in SCL22A1 also failed to influence metformin AUC 0-48. A recent study using noninvasive 11 C-metformin PET/CT scan revealed a novel implication of SLC22A1 polymorphisms: the hepatic uptake of metformin was significantly reduced in carriers of rs12208357 (and rs72552763) irrespective of changes in circulating levels of metformin. This led to the conclusion that plasma levels of metformin do not reflect the drug concentration in hepatocytes where it exerts its pharmacodynamic effects [36] . In addition to rs12208357, the final multivariate regression model of covariates significantly associated with metformin AUC 0-48 retained age, BSA, food and individual proportions of African ancestry. Metformin AUC 0-48 increased with age and food but was inversely associated with BSA and individual proportion of African ancestry. The effect of age on systemic exposure to metformin has been reported previously and ascribed to age-related decline in kidney function [37] . Our cohort ranged in age from 18 to 48 years, and studies using GFR estimates on population-based data suggested that the decline of kidney function may begin after the second decade of life [38] . The greater metformin AUC 0-48h in fed compared to fasted subjects in our study contrasts with previous reports of decreased or no change in bioavailability of metformin after high-fat and/or highcalorie meals [39] [40] [41] . Differences in fat and caloric content across studies may account for these discordant observations. The inverse relationship between BSA and metformin AUC 0-48 in our cohort is a likely consequence of increasing volume of distribution with the increase in BSA. Finally, the inverse relationship between African ancestry and metformin AUC 0-48h is a novel observation which was made possible by enrolment of an admixed Brazilian cohort covering a wide range of individual proportions of European and African ancestry ( Figure S1 ). Of notice, the individual selfreported race/Colour was not retained in the final model, which is consistent with the notion that among Brazilians, correlation between skin colour and biogeographical ancestry is tenuous, at best [13, 15, 42] . Nevertheless, the inverse relationship between African ancestry and metformin AUC 0-48h is in line with the higher apparent clearance of metformin in African Americans, compared to European Americans [7] . Accordingly, Goswami et al. [7] concluded that "for African Americans to achieve similar metformin exposure to that of European Americans a 26% increase in dose should be considered". Importantly, attempts to extrapolate data from African Americans to Black Brazilians must take into consideration that although individual proportions of African ancestry vary widely among both groups, the average proportion of African ancestry is considerably higher in African Americans, compared to Black Brazilians [11] .
During the editorial reviewing process, it has been suggested that it would be interesting to use the remaining 150 individuals in the overall cohort to validate the final regression model for metformin AUC 0-48 . We agree and acknowledge as a limitation of the study the impossibility of carrying out such validation, because DNA from the remaining individuals was not available for genotyping the pharmacogenetic polymorphisms or the ancestry informative markers.
In conclusion, using the EDP approach and a multivariate regression modelling we identified a pharmacogenetic marker in OCT1 (SLC22A1 rs12208357), which combined with demographic covariates (age, BSA and individual proportion of African ancestry) and a food effect explained 29% of the variability in the systemic exposure to metformin, administered as a single dose to an admixed Brazilian cohort of healthy subjects. Whether these findings may be extended to DM2 patients under chronic treatment with metformin requires further studies.
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